Corbus Pharma (CRBP) Tops Q4 EPS by 15c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021 7:05 AM EDTÂ Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Â Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with clinical studies projected for... More
